Page 1 | Search Results | Blood Advances | American Society of Hematology

1-20 of 20

Sort by

Sort Order Select

Journal Articles

PI3Kδ activation, IL-6 overexpression, and CD37 loss cause resistance to naratuximab emtansine in lymphomas

Blood Adv (2024) 8 (24): 6268–6281.

https://doi.org/10.1182/bloodadvances.2023012291

Published: 2024

Includes: Supplemental data

Journal Articles

A phase 1 study of the CDK9 inhibitor voruciclib in relapsed/refractory acute myeloid leukemia and B-cell malignancies

Matthew S. Davids, Danielle M Brander, Yesid Alvarado Valero, Catherine Sibyl Diefenbach, Daniel Nathan Egan, Shira Naomi Dinner, Nathalie Javidi-Sharifi, Monzr M. Al Malki, Kebede Begna, Vijaya R. Bhatt, Sameem Abedin, Rachel Cook, Mary C. Collins, Carly Roleder, Edward C Dominguez, Prabhu Rajagopalan, Sandra E Wiley, Richard G Ghalie, Alexey V Danilov

Blood Adv bloodadvances.2024014633.

https://doi.org/10.1182/bloodadvances.2024014633

Published: 2024

Includes: Supplemental data

Journal Articles

Myeloid clonal hematopoiesis of indeterminate potential in patients with chronic lymphocytic leukemia

Abi Vijenthira, Virginia O. Volpe, Aswin Sekar, Roberta Santos Azevedo, Mariia Mikhaleva, Christopher J. Gibson, Stephen P. Martindale, Rayan Fardoun, Svitlana Tyekucheva, Yue Ren, Stacey M. Fernandes, Binyamin A. Knisbacher, Cynthia K. Hahn, Gad Getz, Catherine J. Wu, Matthew S. Davids, Jennifer R. Brown

Blood Adv (2024) 8 (23): 5949–5956.

https://doi.org/10.1182/bloodadvances.2024013414

Published: 2024

Includes: Supplemental data

Journal Articles

Acalabrutinib-based regimens in frontline or relapsed/refractory higher-risk CLL: pooled analysis of 5 clinical trials

Matthew S. Davids, Jeff P. Sharman, Paolo Ghia, Jennifer A. Woyach, Toby A. Eyre, Wojciech Jurczak, Tanya Siddiqi, Paulo Miranda, Mina Shahkarami, Anna Butturini, Ugochinyere Emeribe, John C. Byrd

Blood Adv (2024) 8 (13): 3345–3359.

https://doi.org/10.1182/bloodadvances.2023011307

Published: 2024

Includes: Supplemental data

Journal Articles

An indirect comparison of acalabrutinib with and without obinutuzumab vs zanubrutinib in treatment-naive CLL

Adam S. Kittai, John N. Allan, Dan James, Helen Bridge, Miguel Miranda, Alan S. M. Yong, Fady Fam, Jack Roos, Vikram Shetty, Alan Skarbnik, Matthew S. Davids

Blood Adv (2024) 8 (11): 2861–2869.

https://doi.org/10.1182/bloodadvances.2023012142

Published: 2024

Includes: Supplemental data

Journal Articles

A multicenter study of venetoclax-based treatment for patients with Richter transformation of chronic lymphocytic leukemia

Paul J. Hampel, Mahesh Swaminathan, Kerry A. Rogers, Erin M. Parry, Jan A. Burger, Matthew S. Davids, Wei Ding, Alessandra Ferrajoli, Jonathan M. Hyak, Nitin Jain, Saad S. Kenderian, Yucai Wang, William G. Wierda, Jennifer A. Woyach, Sameer A. Parikh, Philip A. Thompson

Blood Adv (2024) 8 (10): 2342–2350.

https://doi.org/10.1182/bloodadvances.2023012080

Published: 2024

Includes: Supplemental data

Journal Articles

Six-year follow-up and subgroup analyses of a phase 2 trial of venetoclax for del(17p) chronic lymphocytic leukemia

Blood Adv (2024) 8 (8): 1992–2004.

https://doi.org/10.1182/bloodadvances.2023011741

Published: 2024

Includes: Supplemental data

Journal Articles

Five-year follow-up of a phase 2 study of ibrutinib plus fludarabine, cyclophosphamide, and rituximab as initial therapy in CLL

Blood Adv (2024) 8 (4): 832–841.

https://doi.org/10.1182/bloodadvances.2023011574

Published: 2024

Includes: Supplemental data

Journal Articles

Limited efficacy for ibrutinib and venetoclax in T-prolymphocytic leukemia: results from a phase 2 international study

Blood Adv (2024) 8 (4): 842–845.

https://doi.org/10.1182/bloodadvances.2023012248

Published: 2024

Includes: Supplemental data

Journal Articles

Targeting conditioned media dependencies and FLT-3 in chronic lymphocytic leukemia

Salma Parvin, Aditi Aryal, Shanye Yin, Geoffrey G. Fell, Matthew S. Davids, Catherine J. Wu, Anthony Letai

Blood Adv (2023) 7 (19): 5877–5889.

https://doi.org/10.1182/bloodadvances.2022008207

Published: 2023

Includes: Supplemental data

Journal Articles

Minimal residual disease in patients with diffuse large B-cell lymphoma undergoing autologous stem cell transplantation

Blood Adv (2023) 7 (17): 4748–4759.

https://doi.org/10.1182/bloodadvances.2022007706

Published: 2023

Includes: Supplemental data

Journal Articles

Diminished humoral and cellular responses to SARS-CoV-2 vaccines in patients with chronic lymphocytic leukemia

Blood Adv (2023) 7 (17): 4728–4737.

https://doi.org/10.1182/bloodadvances.2022009164

Published: 2023

Includes: Supplemental data

Journal Articles

Pirtobrutinib targets BTK C481S in ibrutinib-resistant CLL but second-site BTK mutations lead to resistance

Blood Adv (2023) 7 (9): 1929–1943.

https://doi.org/10.1182/bloodadvances.2022008447

Published: 2023

Includes: Supplemental data

Journal Articles

Integrated safety analysis of umbralisib, a dual PI3Kδ/CK1ε inhibitor, in relapsed/refractory lymphoid malignancies

Blood Adv (2021) 5 (23): 5332–5343.

https://doi.org/10.1182/bloodadvances.2021005132

Published: 2021

Includes: Supplemental data

Journal Articles

Activity of mRNA COVID-19 vaccines in patients with lymphoid malignancies

Jennifer L. Crombie, Amy C. Sherman, Chi-An Cheng, Christine E. Ryan, Rebecca Zon, Michaël Desjardins, Peter Baker, Mikaela McDonough, Natalie Izaguirre, Bruce Bausk, Jonathan Krauss, Tal Gilboa, Yasmeen Senussi, David R. Walt, Matthew S. Davids, Jennifer R. Brown, Philippe Armand, Lindsey R. Baden, Nicolas Issa

Blood Adv (2021) 5 (16): 3062–3065.

https://doi.org/10.1182/bloodadvances.2021005328

Published: 2021

Journal Articles

Pneumocystis jirovecii pneumonia and institutional prophylaxis practices in CLL patients treated with BTK inhibitors

Christine E. Ryan, Matthew P. Cheng, Nicolas C. Issa, Jennifer R. Brown, Matthew S. Davids

Blood Adv (2020) 4 (7): 1458–1463.

https://doi.org/10.1182/bloodadvances.2020001678

Published: 2020

Journal Articles

The Connect CLL Registry: final analysis of 1494 patients with chronic lymphocytic leukemia across 199 US sites

Anthony Mato, Chadi Nabhan, Nicole Lamanna, Neil E. Kay, David L. Grinblatt, Christopher R. Flowers, Charles M. Farber, Matthew S. Davids, Arlene S. Swern, Kristen Sullivan, E. Dawn Flick, Sarah M. Gressett Ussery, Mecide Gharibo, Pavel Kiselev, Jeff P. Sharman

Blood Adv (2020) 4 (7): 1407–1418.

https://doi.org/10.1182/bloodadvances.2019001145

Published: 2020

Includes: Supplemental data

Journal Articles

Rituximab/bendamustine and rituximab/cytarabine induction therapy for transplant-eligible mantle cell lymphoma

Blood Adv (2020) 4 (5): 858–867.

https://doi.org/10.1182/bloodadvances.2019001355

Published: 2020

Includes: Supplemental data

Journal Articles

Efficacy results of a phase 2 trial of first-line idelalisib plus ofatumumab in chronic lymphocytic leukemia

Benjamin L. Lampson, Haesook T. Kim, Matthew S. Davids, Jeremy S. Abramson, Arnold S. Freedman, Caron A. Jacobson, Philippe A. Armand, Robin M. Joyce, Jon E. Arnason, Laura Z. Rassenti, Thomas J. Kipps, Joshua Fein, Stacey M. Fernandes, John R. Hanna, David C. Fisher, Jennifer R. Brown

Blood Adv (2019) 3 (7): 1167–1174.

https://doi.org/10.1182/bloodadvances.2018030221

Published: 2019

Includes: Supplemental data

Journal Articles

Early progression of disease as a predictor of survival in chronic lymphocytic leukemia

Inhye E. Ahn, Charles M. Farber, Matthew S. Davids, David L. Grinblatt, Neil E. Kay, Nicole Lamanna, Anthony Mato, Chadi Nabhan, Pavel Kiselev, Arlene S. Swern, E. Dawn Flick, Kristen Sullivan, Jeff P. Sharman, Christopher R. Flowers

Blood Adv (2017) 1 (25): 2433–2443.

https://doi.org/10.1182/bloodadvances.2017011262

Published: 2017

Includes: Supplemental data

NARROW

PI3Kδ activation, IL-6 overexpression, and CD37 loss cause resistance to naratuximab emtansine in lymphomas

A phase 1 study of the CDK9 inhibitor voruciclib in relapsed/refractory acute myeloid leukemia and B-cell malignancies

Myeloid clonal hematopoiesis of indeterminate potential in patients with chronic lymphocytic leukemia

Acalabrutinib-based regimens in frontline or relapsed/refractory higher-risk CLL: pooled analysis of 5 clinical trials

An indirect comparison of acalabrutinib with and without obinutuzumab vs zanubrutinib in treatment-naive CLL

A multicenter study of venetoclax-based treatment for patients with Richter transformation of chronic lymphocytic leukemia

Six-year follow-up and subgroup analyses of a phase 2 trial of venetoclax for del(17p) chronic lymphocytic leukemia

Five-year follow-up of a phase 2 study of ibrutinib plus fludarabine, cyclophosphamide, and rituximab as initial therapy in CLL

Limited efficacy for ibrutinib and venetoclax in T-prolymphocytic leukemia: results from a phase 2 international study

Targeting conditioned media dependencies and FLT-3 in chronic lymphocytic leukemia

Minimal residual disease in patients with diffuse large B-cell lymphoma undergoing autologous stem cell transplantation

Diminished humoral and cellular responses to SARS-CoV-2 vaccines in patients with chronic lymphocytic leukemia

Pirtobrutinib targets BTK C481S in ibrutinib-resistant CLL but second-site BTK mutations lead to resistance

Integrated safety analysis of umbralisib, a dual PI3Kδ/CK1ε inhibitor, in relapsed/refractory lymphoid malignancies

Activity of mRNA COVID-19 vaccines in patients with lymphoid malignancies

Pneumocystis jirovecii pneumonia and institutional prophylaxis practices in CLL patients treated with BTK inhibitors

The Connect CLL Registry: final analysis of 1494 patients with chronic lymphocytic leukemia across 199 US sites

Rituximab/bendamustine and rituximab/cytarabine induction therapy for transplant-eligible mantle cell lymphoma

Efficacy results of a phase 2 trial of first-line idelalisib plus ofatumumab in chronic lymphocytic leukemia

Early progression of disease as a predictor of survival in chronic lymphocytic leukemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only